Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/29/2022* -- Results Q2 2022 -- 0.30 --
07/29/2022* 16:30 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 0.76 0.66 15.65%
05/04/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/17/2022 -- Results Q4 2021 1.80 1.37 31.40%
02/17/2022 16:30 EST Earnings Call Q4 2021 -- -- --
11/09/2021 -- Results Q3 2021 1.58 1.04 52.41%
11/09/2021 16:30 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/29/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/04/2022
Beat/Miss Upgrade
Return Since -13.67%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
URL http://www.ligand.com
Investor Relations URL https://investor.ligand.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Jul. 29, 2022 (est.)
Last Earnings Release May. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jul. 02, 2010

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date Jul. 02, 2010
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
103.8%
-6.28%
34.76%
-0.90%
-23.15%
-4.64%
55.31%
-46.34%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
--
-65.10%
241.2%
88.42%
4.84%
-29.80%
-18.29%
-50.43%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-47.16%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-31.57%
-18.25%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-49.00%
As of May 20, 2022.

Profile

Edit
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
URL http://www.ligand.com
Investor Relations URL https://investor.ligand.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Jul. 29, 2022 (est.)
Last Earnings Release May. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jul. 02, 2010

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
VILLX 5.139M USD 3.27%
PJP 8.289M USD 2.69%
PXSCX 18.48M USD 2.58%
BUISX 20.70M USD 1.78%
XDNA.TO 83762.00 USD 1.68%
IDNA 2.937M USD 1.55%
BUITX 26.08M USD 1.48%
WBSRX 9.165M USD 1.41%
SBIO 1.350M USD 1.41%
PSCH 4.376M USD 1.32%
JGMCX 113.66M USD 1.20%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter LGND Tweets